Beat the Market Biotechs Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Beat the Market Biotechs

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: Western Rookie	4/2/2012 7:17:35 PM
	of 72

BXI-V $5.3M in revenue and a $4.7M loss. $43M market cap. Abattis platform allows for a low burn rate and only increased costs with sales with increasing gross margins... What would you rather have? A $2.5M company at $0.05 with little risk as far as SP appreciation buying it low... or a $43M market cap company with increasing increasing losses as revenues increase. Abattis break even point is much lower than BXI-V that is for sure. For Bio-Meds... 10 times revenue is not uncommon... then you add ip value so if Abattis can secure $1M in sales over the next 12 months and demonstrate growth potential... 10 times $1M is a $10M market cap with IP and sales growth. The margins on the Nitric Oxide product are very healthy. BioExx Announces 2011 Annual and Q4 Results

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next